GAVISCON ADVANCE

This brand name is authorized in Hong Kong SAR China, Ireland, Malta, Poland, Singapore, Turkey, UK.

Active ingredients

The drug GAVISCON ADVANCE contains a combination of these active pharmaceutical ingredients (APIs):

1	Alginic acid UNII C269C4G2ZQ - SODIUM ALGINATE
	Alginic acid is a polysaccharide distributed widely in the cell walls of brown algae which is hydrophilic and forms a viscous gum when hydrated. Its salts with metals such as sodium and calcium are known as alginates. It is a significant component of the biofilms produced by the bacterium Pseudomonas aeruginosa, a major pathogen found in the lungs of some people who have cystic fibrosis. The biofilm and P. aeruginosa have a high resistance to antibiotics and are susceptible to inhibition by macrophages.
	Read more about Alginic acid
2	Potassium bicarbonate UNII HM5Z15LEBN - POTASSIUM BICARBONATE
	Read more about Potassium bicarbonate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Discover more medicines within A02BX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	216783, 280079, 30279, 30281, 387040, 43767, 43769, 46052, 93068, 93069
HK	Department of Health Drug Office	52788, 58057
IE	Health Products Regulatory Authority	26523, 26572
MT	Medicines Authority	AA846/00103, MA096/00304, MA096/00305
PL	Rejestru Produktów Leczniczych	100229320
SG	Health Sciences Authority	12635P
TR	İlaç ve Tıbbi Cihaz Kurumu	8690570700046